BioProtect
Kfar Saba, Israel· Est.
Innovative balloon spacer that enhances prostate radiotherapy safety and efficacy.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Innovative balloon spacer that enhances prostate radiotherapy safety and efficacy.
Oncology
Technology Platform
A pre‑formed, resorbable balloon that creates a uniform 10–18 mm prostate‑rectum separation, improving radiotherapy dosimetry and reducing rectal toxicity.
Opportunities
Geographic expansion, new indications in other pelvic cancers, and next‑generation spacer designs could drive significant market growth.
Risk Factors
Regulatory reimbursement uncertainty, competition from gel spacers, and manufacturing scaling challenges pose key risks.
Competitive Landscape
Main competitors include SpaceOAR and other PEG‑based gel spacers; BioProtect differentiates through superior symmetry, greater apical spacing, and rapid resorption.